ApoB vs LDL-C and Non-HDL-C as the Primary Measure of ApoB Lipoprotein-Related Risk: The Debate Is Over

This is the print version of Sniderman’s emphatically titled viewpoint, “The Debate Is Over” — the case that ApoB has decisively beaten LDL cholesterol as the measure of atherogenic risk.

Its argument rests on discordance analysis and Mendelian randomization. When ApoB and LDL-C diverge, risk follows ApoB; and genetically, the risk reduction from lowering LDL is proportional to the accompanying change in ApoB — mechanisms that lower cholesterol without lowering particle number don’t deliver the same benefit. That isolates the ApoB particle as the causal unit of atherosclerosis.

The practical takeaway is to prioritize ApoB for risk assessment and treatment monitoring, particularly in metabolic syndrome, diabetes, and hypertriglyceridemia. The resistance is the entrenched LDL-C habit and assay-cost misperceptions.

We rate the evidence strong: a brief viewpoint, but synthesizing the highest-quality causal and prospective evidence available. Its clinical significance is very high — a fundamental upgrade in how cardiovascular risk is measured. (Note: this is the same JAMA Cardiology article as the “Sniderman et al., 2021” entry in our library — duplicated as online and print versions; keep one.)